ストックスクリーナーアプリを入手
3.74
0.81%
0.03
前日終値:
$3.71
開ける：
$3.7
24時間の取引高:
980.41K
Relative Volume:
0.39
時価総額：
$285.35M
収益：
$80.00M
当期純損益:
$-76.12M
株価収益率:
-3.2621
EPS:
-1.1465
ネットキャッシュフロー:
$-63.88M
1週間 パフォーマンス:
-3.86%
1か月 パフォーマンス:
+4.18%
6か月 パフォーマンス:
-64.82%
1年 パフォーマンス:
-43.33%
1日の値動き範囲:
$3.65
$3.755
1週間の範囲:
$3.615
$3.87
52週間の値動き範囲:
$2.83
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
名前
Fulcrum Therapeutics Inc
セクター
電話
617-651-8851
住所
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
3.74 | 283.83M | 80.00M | -76.12M | -63.88M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-12 | 開始されました | JP Morgan | Overweight |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-07-29 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-09-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | ダウングレード | Stifel | Buy → Hold |
| 2024-09-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-09-25 | 開始されました | Goldman | Neutral |
| 2023-08-23 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | アップグレード | Stifel | Hold → Buy |
| 2023-05-04 | ダウングレード | Goldman | Buy → Neutral |
| 2023-03-10 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2023-02-28 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 開始されました | Goldman | Buy |
| 2022-03-08 | 開始されました | Oppenheimer | Outperform |
| 2022-03-03 | アップグレード | BofA Securities | Underperform → Neutral |
| 2021-08-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-03-22 | 開始されました | Credit Suisse | Outperform |
| 2021-03-02 | 開始されました | Stifel | Buy |
| 2020-10-16 | 開始されました | Piper Sandler | Overweight |
| 2020-08-12 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-12 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-08-12 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Fulcrum Therapeutics Inc (FULC) 最新ニュース
Therapeutics, Inc. (FULC) RA Capital group now reports 0.0% stake - Stock Titan
Therapeutics, Inc. (FULC) 8.22% stake disclosed by Nantahala Capital - Stock Titan
Fulcrum Therapeutics (FULC): Montanova and affiliates report 5.5% ownership stake - Stock Titan
Fulcrum Therapeutics (FULC) investor group reduces reported ownership to 0% - Stock Titan
Kaplan Fox Investigates Fulcrum Therapeutics After 51% Stock Plunge Following Pociredir Program Halt - Kalkine Media
Assenagon Asset Management S.A. Has $3.06 Million Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Kaplan Fox Reminds Investors of Fulcrum Therapeutics, Inc. (NASDA - The National Law Review
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: FULC) for Potential Securities Law Violations - FinancialContent
Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Halt - Kalkine Media
Fulcrum Therapeutics Faces Securities Law Investigation After Pociredir Program Discontinuation Triggers 51% Stock Drop - kalkine.ca
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (NA - The National Law Review
Fulcrum Therapeutics stock plunges 51% after FD... - Pluang
Fulcrum Therapeutics Appoints Alan Musso as Principal Accounting Officer Amid Leadership Change - Kalkine Media
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer By Investing.com - Investing.com Nigeria
Form 8K Fulcrum Therapeutics Inc For: 10 August By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics appoints Alan Musso as principal accounting officer - Investing.com
Fulcrum Therapeutics, Inc. Appoints Alan Musso as Principal Accounting Officer, Effective August 7, 2026 - marketscreener.com
Fulcrum Therapeutics Inc (FULC) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Fulcrum Therapeutics(FULC.US) With Sell Rating, Maintains Target Price $3 - Moomoo
FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Reduce" from Analysts - MarketBeat
Fulcrum Therapeutics Stock Drops 51% After Pociredir Discontinuation as Law Firm Launches Securities Investigation - kalkine.ca
Fulcrum Therapeutics (FULC) Stock Sees Modest Fair Value Lift After Pociredir Exit - Yahoo Finance
Bank of America (NYSE: BAC) reports 6.7% holding in Fulcrum Therapeutics (FULC) - Stock Titan
Fulcrum Therapeutics (FULC) Gets a Hold from Truist Financial - The Globe and Mail
Truist Financial Downgrades Fulcrum Therapeutics(FULC.US) to Hold Rating, Cuts Target Price to $4 - Moomoo
Fulcrum Therapeutics (NASDAQ:FULC) Posts Earnings Results, Misses Expectations By $0.13 EPS - MarketBeat
Fulcrum Therapeutics, Inc. 2Q 2026: Net loss $(26.2M), EPS $(0.34) — 10-Q Summary - tradingview.com
Kaplan Fox Initiates Securities Probe into Fulcrum Therapeutics After Halting Pociredir Program Amid FDA Safety Concerns - Kalkine Media
Kaplan Fox Launches Securities Investigation into Fulcrum Therapeutics Following Pociredir Program Discontinuation - kalkine.ca
BlackRock discloses 7.2% ownership of Therapeutics Inc (FULC) in updated filing - Stock Titan
Fulcrum Therapeutics Inc (FULC) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Fulcrum Therapeutics Inc (FULC) Institutional Confidence - TradingKey
Fulcrum Therapeutics Inc (FULC) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kaplan Fox Launches Securities Probe Into Fulcrum Therapeutics After Pociredir Program Halt Sparks Stock Plunge - Kalkine Media
Fulcrum Therapeutics Inc (FULC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Fulcrum Therapeutics Inc (FULC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Fulcrum Therapeutics Inc (FULC) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Fulcrum Therapeutics Inc (FULC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Fulcrum Therapeutics, Inc. Revenue Breakdown – NASDAQ:FULC - tradingview.com
ETFs Investing in Fulcrum Therapeutics, Inc. Stocks - TradingView
Fulcrum Therapeutics Inc (FULC) Cash Flow - TradingKey
FULC|Fulcrum Therapeutics Inc|Price:3.725|Chg%:+0.005 - TradingKey
Kaplan Fox Encourages Investors of Fulcrum Therapeutics, Inc. (FULC) Who Suffered Losses to Contact the Firm Regarding a Securities Investigation - TMX Newsfile
Siren L.L.C. Increases Position in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Kaplan Fox is Investigating Fulcrum Therapeutics, Inc. (NASDAQ: F - The National Law Review
TANG CAPITAL MANAGEMENT LLC Increases Stake in Fulcrum Therapeutics Inc. - GuruFocus
Kaplan Fox Announces an Investigation Into Fulcrum Therapeutics - The National Law Review
Fulcrum Therapeutics 10% owner Kevin Tang acquires $594,132 of common shares - Bitget
Fulcrum Therapeutics: director Kevin Tang buys $594k in shares By Investing.com - Investing.com Australia
Form 4 Fulcrum Therapeutics Inc For: 21 July By Investing.com - Investing.com Nigeria
Fulcrum Therapeutics Inc (FULC) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):